Literature DB >> 12464247

Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid.

Armelle Melet1, Nadine Assrir, Pascale Jean, Maria Pilar Lopez-Garcia, Cristina Marques-Soares, Maryse Jaouen, Patrick M Dansette, Marie Agnès Sari, Daniel Mansuy.   

Abstract

A series of six site-directed mutants of CYP 2C9 were constructed with the aim to better define the amino acid residues that play a critical role in substrate selectivity of CYP 2C9, particularly in three distinctive properties of this enzyme: (i) its selective mechanism-based inactivation by tienilic acid (TA), (ii) its high affinity and hydroxylation regioselectivity toward diclofenac, and (iii) its high affinity for the competitive inhibitor sulfaphenazole (SPA). The S365A mutant exhibited kinetic characteristics for the 5-hydroxylation of TA very similar to those of CYP 2C9; however, this mutant did not undergo any detectable mechanism-based inactivation by TA, which indicates that the OH group of Ser 365 could be the nucleophile forming a covalent bond with an electrophilic metabolite of TA in TA-dependent inactivation of CYP 2C9. The F114I mutant was inactive toward the hydroxylation of diclofenac; moreover, detailed analyses of its interaction with a series of SPA derivatives by difference visible spectroscopy showed that the high affinity of SPA to CYP 2C9 (K(s)=0.4 microM) was completely lost when the phenyl substituent of Phe 114 was replaced with the alkyl group of Ile (K(s)=190+/-20 microM), or when the phenyl substituent of SPA was replaced with a cyclohexyl group (K(s)=120+/-30 microM). However, this cyclohexyl derivative of SPA interacted well with the F114I mutant (K(s)=1.6+/-0.5 microM). At the opposite end, the F94L and F110I mutants showed properties very similar to those of CYP 2C9 toward TA and diclofenac. Finally, the F476I mutant exhibited at least three main differences compared to CYP 2C9: (i) big changes in the k(cat) and K(m) values for TA and diclofenac hydroxylation, (ii) a 37-fold increase of the K(i) value found for the inhibition of CYP 2C9 by SPA, and (iii) a great change in the regioselectivity of diclofenac hydroxylation, the 5-hydroxylation of this substrate by CYP 2C9 F476I exhibiting a k(cat) of 28min(-1). These data indicate that Phe 114 plays an important role in recognition of aromatic substrates of CYP 2C9, presumably via Pi-stacking interactions. They also provide the first experimental evidence showing that Phe 476 plays a crucial role in substrate recognition and hydroxylation by CYP 2C9.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12464247     DOI: 10.1016/s0003-9861(02)00548-9

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  15 in total

Review 1.  Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2021-01-18       Impact factor: 5.153

2.  The dynamics of camphor in the cytochrome P450 CYP101D2.

Authors:  Shabana Vohra; Maria Musgaard; Stephen G Bell; Luet-Lok Wong; Weihong Zhou; Philip C Biggin
Journal:  Protein Sci       Date:  2013-08-12       Impact factor: 6.725

3.  Selective, competitive and mechanism-based inhibitors of human cytochrome P450 2J2.

Authors:  Pierre Lafite; Sylvie Dijols; Darryl C Zeldin; Patrick M Dansette; Daniel Mansuy
Journal:  Arch Biochem Biophys       Date:  2007-04-10       Impact factor: 4.013

4.  The role of Ile476 in the structural stability and substrate binding of human cytochrome P450 2C8.

Authors:  Lu Sun; Zhong-Hua Wang; Feng-Yun Ni; Xiang-Shi Tan; Zhong-Xian Huang
Journal:  Protein J       Date:  2010-01       Impact factor: 2.371

5.  Effective virtual screening protocol for CYP2C9 ligands using a screening site constructed from flurbiprofen and S-warfarin pockets.

Authors:  Tímea Polgár; Dóra K Menyhárd; György M Keseru
Journal:  J Comput Aided Mol Des       Date:  2007-10-25       Impact factor: 3.686

6.  Functional analysis of phenylalanine residues in the active site of cytochrome P450 2C9.

Authors:  Carrie M Mosher; Matthew A Hummel; Timothy S Tracy; Allan E Rettie
Journal:  Biochemistry       Date:  2008-10-16       Impact factor: 3.162

7.  Re-engineering of CYP2C9 to probe acid-base substrate selectivity.

Authors:  Guoying Tai; Leslie J Dickmann; Nicholas Matovic; James J DeVoss; Elizabeth M J Gillam; Allan E Rettie
Journal:  Drug Metab Dispos       Date:  2008-07-07       Impact factor: 3.922

8.  Case Study 9: Probe-Dependent Binding Explains Lack of CYP2C9 Inactivation by 1-Aminobenzotriazole (ABT).

Authors:  Jasleen K Sodhi; Jason S Halladay
Journal:  Methods Mol Biol       Date:  2021

9.  Mechanism-based inactivation of cytochrome P450 2C9 by tienilic acid and (+/-)-suprofen: a comparison of kinetics and probe substrate selection.

Authors:  J Matthew Hutzler; Larissa M Balogh; Michael Zientek; Vikas Kumar; Timothy S Tracy
Journal:  Drug Metab Dispos       Date:  2008-10-06       Impact factor: 3.922

10.  Structural Basis of Single-Nucleotide Polymorphisms in Cytochrome P450 2C9.

Authors:  Keiko Maekawa; Motoyasu Adachi; Yumiko Matsuzawa; Qinghai Zhang; Ryota Kuroki; Yoshiro Saito; Manish B Shah
Journal:  Biochemistry       Date:  2017-10-03       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.